Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    NCT01774851
Show Display Options
Rank Status Study
1 Recruiting A Study of MM-111 and Paclitaxel With Trastuzumab in Patients HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach
Conditions: HER-2 Gene Amplification;   Esophagus Cancer;   Gastroesophageal Junction Cancer;   Stomach Cancer
Interventions: Drug: MM-111;   Drug: Paclitaxel;   Drug: Trastuzumab

Indicates status has not been verified in more than two years